CD95-Dependent T-Cell Killing by Glioma Cells Expressing CD95 Ligand: More on Tumor Immune Escape, the CD95 Counterattack, and the Immune Privilege of the Brain

Cellular Physiology and Biochemistry

Volumn 7, Issue 5, 1997, Pages 282-288

  Weller, Michael ^a   Weinstock, Christoph ^b   Will, Christine ^a,c   Wagenknecht, Bettina ^a   Dichgans, Johannes ^a   Lang, Florian ^c   Gulbins, Erich ^c  

^a The Department of Neurology   (Germany)

^b Transfusion Medicine and Physiology   (Germany)

^c UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

Apoptosis; Fas CD95 APO 1; Glioma; Lymphocytes

Indexed keywords

FAS ANTIGEN; LIGAND;

ANTIGEN EXPRESSION; ARTICLE; CELL DEATH; COCULTURE; CONTROLLED STUDY; FLOW CYTOMETRY; GLIOBLASTOMA; HUMAN; HUMAN CELL; IN VITRO STUDY; PRIORITY JOURNAL; T LYMPHOCYTE; TUMOR CELL;

EID: 0030883910     PISSN: 10158987     EISSN: 14219778     Source Type: Journal    
DOI: 10.1159/000154883     Document Type: Article

References (18)

1. Gulbins E., Szabo I., Lang F: Physiology of Fas-induced programmed cell death., Cell Physiol Biochem 1996:6: 361-375.
2. Schlottmann K, Coggcshall KM: CD95/Fas/APO-l-mediated signal transduction., Cell Physiol Biochem 1996;6:345-360.
3. Weller M, Frci K, Groscurth P., Krammer PH, Yonekawa Y., Fontana A: Anti-Fas/APO-l antibody-mediated apoptosis of cultured human glioma cells., Induction and modulation of sensitivity by cytokines., J Clin Invest 1994;94:954-964.
4. Weller M., Malipiero UV., Aguzzi A, Reed JC, Fontana A: Protooncogcnc bcl-2 gene transfer abrogates Fas/ APO-1 antibody-mediated apoptosis of human malignant glioma cells and confers resistance to chemotherapeutic drugs and irradiation., J Clin Invest 1995;95:2633-2643.
5. Weller M, Malipiero U., Rensing-Eh A, Barr P., Fontana A: Fas/APO-1 gene transfer for human malignant glioma., Cancer Res 1995:55:2936-2944.
6. Roth W., Fontana A, Trepel M, Dich-gans J, Reed JC, Weller M: Immuno-chemotherapy of malignant glioma: synergistic activity of CD95 ligand and chcmothcrapeutics., Cancer Immunol Immunother 1997;44:55-63.
7. Weller M: Genetic regulation and therapeutic modulation of apoptosis in human malignant glioma., Cell Phvsiol Biochem 1996:6:376-380.
8. Tachibana O., Nakazawa H, Lampe J., Watanabe K., Klcihues P., Ohgaki H: Expression of Fas/APO-l during the progression of astrocytomas., Cancer Res 1995;55:5528-5530.
9. O’Connell J, O’Sullivan GC, Collins JK, Shanahan S: The Fas counterattack: Fas-mcdiatcd T cell killing by colon cancer cells expressing Fas ligand., J Exp Med 1996:184:1075-1082.
10. Hahne M., Rimoldi D., Schroter M., Romero P, Schreier M, French LE, Schneider P., Bontand T, Fortana A., Lienard D., Cerottini JC, Tschopp J: Melanoma cell expression of Fas (APO-1/CD95) ligand: Implications for tumor immune escape., Science 1996:274:1363-1366.
11. Strand S, Hofmann WJ, Hug H., Miillcr M., Otto G, Strand D., Mar-iani SM., Strcmmel W, Klammer PH., Galle PR: Lymphocyte apoptosis induced by CD95 (APO-l/Fas) ligand-expressing tumor cells: A mechanism of immune evasion? Nature Med 1996:2:1361-1366.
12. Rensing Ehl A., Frei K., Flurv R., Ma-tiba B., Mariani SM., Weller M., Ae-bischcr P, Krammer PH, Fontana A: Local Fas/APO-l/CD95 ligand-mediated tumor cell killing in vivo., Eur J Immunol 1995:25:2253-2258.
13. Gulbins E., Bissonette R., Mahboubi A, Nishioka W., Brunner T., Baier G., Baier-Bitterlich G., Byrd C., Lang F., Kolesnick R., Altman A, Green D: Fas-induced apoptosis is mediated via a ceramide-initiated RAS signaling pathway., Immunity 1995:2: 341-351.
14. Weller M., Fontana A: The failure of current immunotherapy for malignant glioma: Tumor-derived TGF-p., T-ccll apoptosis, and the immune privilege of the brain., Brain Res Rev 1995:21:128-151.
15. Weller M., Constam DB, Malipiero U., Fontana A: Transforming growth factor-p2 induces apoptosis of murine T cell clones without down-regulating bcl-2 mRNA expression., Eur J Immunol 1995:24:1293-1298.
16. Bellgrau D, Gold D., Selawry H., Moore J., Franzusoff A., Duke RC: A role for CD95 ligand in preventing graft rejection., Nature 1995:377: 630-632.
17. Griffith TS., Brunner T., Fletcher SM., Green DR, Ferguson TA: Fas ligand-induced apoptosis as a mechanism of immune privilege., Science 1995:270:1189-1192.
18. French LE, Hahne M., Viard I., Radlgruber G., Zanone R., Becker K., Miillcr C, Tschopp J: Fas and Fas ligand in embryos and adult mice: Ligand expression in several immune-privileged tissues and coexpression in adult tissues characterized by apoptotic cell turnover., J Cell Biol 1996;133:335-343